AbbVie (ABBV) Announces Venetoclax Phase 2 Met Primary Endpoint in CLL
Tweet Send to a Friend
AbbVie (NYSE: ABBV) announced that a Phase 2 trial of its investigational medicine venetoclax met its primary endpoint of achieving ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
